Skip to content
Search

Latest Stories

Children born preterm at increased risk of mental disorders: Study

While motor impairment refers to a physical disability and could result in muscle weakness, poor stamina, reduced balance, or poor co-ordination, epileptic impairment pertains to a disorder of the central nervous system

Children born preterm at increased risk of mental disorders: Study

A study involving over a million children has found that those born preterm are at a higher risk of adverse neurodevelopmental outcomes which can impact their behaviour and learning abilities.

Researchers compared the long-term neurodevelopmental effects of children born at different gestational ages, particularly 32-33 weeks (moderately preterm) and 34-36 weeks (late preterm), compared with 39-40 weeks (full-term).


The team of researchers, including those at Karolinska Institutet, Sweden, found that the highest relative risk for moderately preterm-born children was for motor impairment (nearly five-fold increased risk), followed by epileptic impairment (nearly two-fold increased risk), compared to full term-born children.

While motor impairment refers to a physical disability and could result in muscle weakness, poor stamina, reduced balance, or poor co-ordination, epileptic impairment pertains to a disorder of the central nervous system.

They also found that the highest level of risks for neurodevelopmental impairments appeared from 32 weeks and then gradually declined until 41 weeks, with higher risks present even at 37-38 weeks than at full term.

Their findings are published in The British Medical Journal (BMJ).

While previous studies have shown that children born early have higher risks of neurodevelopmental and behavioural disabilities throughout childhood and adolescence compared with children born at full term, few population-based studies have investigated the long-term neurodevelopmental outcomes of these children, the researchers said.

As the children they studied comprise about 80 per cent of all preterm births, these neurodevelopmental risks should not be underestimated, they said.

For the study, the researchers used the Swedish national registry to include more than 12.5 lakh single-born children without birth defects born in Sweden at 32 to 41 weeks between 1998 and 2012.

Over an average follow-up period of 13 years, the team found that more than 75,000 infants had at least one diagnosis of any neurodevelopmental impairment, with those born moderately or late preterm showing higher risks for any impairment.

Nearly 5,900 infants had motor impairment, more than 27,000 had cognitive impairment, 11,870 had epileptic impairment, 19,700 had visual impairment and about 20,400 had hearing impairment, they found.

Being an observational study, the researchers said they could not establish a causal relationship and also acknowledged that possible under-reporting or misclassification of the diagnoses might result in underestimating the associations found.

However, this was a large, population-based study using high quality comprehensive national registries, making it possible to investigate clinically relevant risks across the spectrum of gestational age, they said.

"Children born moderately or late preterm have higher risks of adverse neurodevelopmental outcomes. The risks should not be underestimated as these children comprise the largest proportion of children born preterm," the team wrote in their study.

"The findings may help professionals and families to better assess risk, follow-up, and healthcare systems planning for children born moderately or late preterm," they wrote.

(PTI)

More For You

Camellia Panjabi's cookbook elevates
vegetables from sides to stars

Camellia Panjabi (Photo: Ursula Sierek)

Camellia Panjabi's cookbook elevates vegetables from sides to stars

RESTAURATEUR and writer Camellia Panjabi puts the spotlight on vegetables in her new book, as she said they were never given the status of a “hero” in the way fish, chicken or prawns are.

Panjabi’s Vegetables: The Indian Way features more than 120 recipes, with notes on nutrition, Ayurvedic insights and cooking methods that support digestion.

Keep ReadingShow less
Spotting the signs of dementia

Priya Mulji with her father

Spotting the signs of dementia

How noticing the changes in my father taught me the importance of early action, patience, and love

I don’t understand people who don’t talk or see their parents often. Unless they have done something to ruin your lives or you had a traumatic childhood, there is no reason you shouldn’t be checking in with them at least every few days if you don’t live with them.

Keep ReadingShow less
HH Guruji performed the Dhwaja Ritual at Ambaji Temple

HH Guruji performed the Dhwaja Ritual at Ambaji Temple

Mahesh Liloriya

The holy town of Ambaji witnessed a spiritually significant day on Sunday as His Holiness Siri Rajrajeshwar Guruji, head of the International Siddhashram Shakti Centre, London, performed the Dhwaja ritual at the historic Ambaji Temple in Gujarat, one of the most revered Shakti Peeths of India.

Keep ReadingShow less
Eco-friendly Ganesh Utsav at Harrow’s Siddhashram Shakti Centre

Eco-friendly Ganesh Utsav at Harrow’s Siddhashram Shakti Centre

Mahesh Liloriya

The International Siddhashram Shakti Centre in Harrow witnessed an inspiring and environmentally responsible celebration of Ganesh Utsav 2025, which concluded on Saturday, 6 September, with the Ganesh Visarjan ritual performed on the sacred occasion of Anant Chaturdashi.

Keep ReadingShow less
Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less